T3	Pharmacological_substance 68 78	olanzapine
N1000 	Reference T3 MeSH:C076029	olanzapine
T6	Pharmacological_substance 183 193	olanzapine
N1001 	Reference T6 MeSH:C076029	olanzapine
T7	Disorder 244 257	schizophrenic
N1 	Reference T7 UMLS:C0036341	schizophrenic
T8	Pharmacological_substance 275 285	olanzapine
N1002 	Reference T8 MeSH:C076029	olanzapine
T13	Disorder 419 449	neuroleptic malignant syndrome
N2 	Reference T13 UMLS:C0027849	neuroleptic malignant syndrome
T14	Disorder 451 454	NMS
N3 	Reference T14 UMLS:C0270699	NMS
N4 	Reference T14 UMLS:C0027849	NMS
T15	Pharmacological_substance 576 586	Olanzapine
N1003 	Reference T15 MeSH:C076029	Olanzapine
T16	Pharmacological_substance 599 627	atypical antipsychotic drugs
T17	Disorder 639 652	muscle injury
N5 	Reference T17 UMLS:C0410256	muscle injury
N6 	Reference T17 UMLS:C1998242	muscle injury
T20	Pharmacological_substance 752 762	olanzapine
N1004 	Reference T20 MeSH:C076029	olanzapine
T24	Pharmacological_substance 1083 1096	antipsychotic
N1005 	Reference T24 MeSH:D014150	antipsychotic
T27	Pharmacological_substance 1212 1222	olanzapine
N1006 	Reference T27 MeSH:C076029	olanzapine
T29	Subject 217 243;258 261	A 39-year-old white Jewish man
T38	Disorder 955 958	NMS
N7 	Reference T38 UMLS:C0270699	NMS
N8 	Reference T38 UMLS:C0027849	NMS
T39	Subject 1005 1013	patients
T48	Disorder 1032 1035	NMS
N9 	Reference T48 UMLS:C0270699	NMS
N10 	Reference T48 UMLS:C0027849	NMS
T1	Disorder 17 51	elevation of serum creatine kinase
T2	Disorder 127 161	elevation of serum creatine kinase
T9	Disorder 299 330	elevated serum CK concentration
T18	Disorder 670 692	elevations of serum CK
T44	Speculation_cue 629 632	may
T40	Subject 912 920	patients
T22	Disorder 1057 1075	serum CK elevation
T25	Disorder 1156 1177	elevation of serum CK
T42	Subject 1005 1013	patients
T5	Speculation_cue 1187 1195	possible
